A lack of prognostic significance regarding ΔNp63 immunoreactivity in lung cancer

Lung Cancer

Volumn 50, Issue 1, 2005, Pages 67-73

  Iwata, Teruo ^a   Uramoto, Hidetaka ^a   Sugio, Kenji ^a   Fujino, Yoshihisa ^b   Oyama, Tsunehiro ^a   Nakata, Shoji ^a   Ono, Kenji ^a   Morita, Masaru ^a   Yasumoto, Kosei ^a  

^a UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

^b CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

Np63; Immunohistochemistry; Lung cancer; P63; Prognostic factor; Squamous cell carcinoma

Indexed keywords

DELTA NP63 PROTEIN; ISOPROTEIN; PARAFFIN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER PATIENT; CANCER SURGERY; CANCER SURVIVAL; CANCER TISSUE; CELL NUCLEUS; CLINICAL OBSERVATION; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOCYTOCHEMISTRY; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; KAPLAN MEIER METHOD; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; OUTCOMES RESEARCH; PRIORITY JOURNAL; PROGNOSIS; PROTEIN ANALYSIS; PROTEIN EXPRESSION; RANK SUM TEST; SAMPLE; SQUAMOUS CELL CARCINOMA; STAINING; TUMOR CELL; TUMOR DIFFERENTIATION;

AGED; AGED, 80 AND OVER; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; DNA-BINDING PROTEINS; FEMALE; GENES, TUMOR SUPPRESSOR; HUMANS; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; PHOSPHOPROTEINS; PROGNOSIS; SURVIVAL ANALYSIS; TRANS-ACTIVATORS; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEINS;

EID: 24744452608     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lungcan.2005.03.039     Document Type: Article

References (24)

1. S.H. Landis, T. Murray, and S. Bolden Cancer statistics CA Cancer J Clin 48 1998 6 29
2. A. Spira, and D.S. Ettinger Multidisciplinary management of lung cancer N Engl J Med 350 2004 379 392
3. Y. Sekido, K.M. Fong, and J.D. Minna Progress in understanding the molecular pathogenesis of human lung cancer Biochim Biophys Acta 1378 1998 21 59
4. G. Melino, X. Lu, and M. Gasco Functional regulation of p73 and p63: development and cancer Trends Biochem Sci 28 2003 663 670
5. E.A. Ratovitski, M. Patturajan, and K. Hibi p53 associates with and targets Delta Np63 into a protein degradation pathway Proc Natl Acad Sci USA 98 2001 1817 1822
6. K. Hibi, B. Trink, and M. Patturajan AIS is an oncogene amplified in squamous cell carcinoma Proc Natl Acad Sci USA 97 2000 5462 5467
7. K. Yamaguchi, L. Wu, and O.L. Caballero Frequent gain of the p40/p51/p63 gene locus in primary head and neck squamous cell carcinoma Int J Cancer 86 2000 684 689
8. H. Nishi, K. Isaka, and Y. Sagawa Mutation and transcription analyses of the p63 gene in cervical carcinoma Int J Oncol 15 1999 1149 1153
9. P.P. Massion, P.M. Taflan, and S.M. Jamshedur Rahman Significance of p63 amplification and overexpression in lung cancer development and prognosis Cancer Res 63 2003 7113 7121
10. R. Parsa, A. Yang, and F. McKeon Association of p63 with proliferative potential in normal and neoplastic human keratinocytes J Invest Dermatol 113 1999 1099 1105
11. F. Koga, S. Kawakami, and J. Kumagai Impaired Delta Np63 expression associates with reduced beta-catenin and aggressive phenotypes of urothelial neoplasms Br J Cancer 88 2003 740 747
12. C.F. Mountain Revisions in the international system for staging lung cancer Chest 111 1997 1710 1717
13. H. Uramoto, T. Osaki, and M. Inoue Fas expression in non-small cell lung cancer: its prognostic effect in completely resected stage III patients Eur J Cancer 35 1999 1462 1465
14. F. Koga, S. Kawakami, and Y. Fujii Impaired p63 expression associates with poor prognosis and uroplakin III expression in invasive urothelial carcinoma of the bladder Clin Cancer Res 9 2003 5501 5507
15. E. Kaplan, and P. Meier Nonparametric estimation from incomplete observations J Am Stat Assoc 53 1958 457 481
16. M. Oren Lonely no more: p53 finds its kin in a tumor suppressor haven Cell 90 1997 829 832
17. A. Yang, M. Kaghad, and Y. Wang p63, a p53 homolog at 3q27-29, encodes multiple products with transactivating, death-inducing, and dominant-negative activities Mol Cell 2 1998 305 316
18. A. Hackzell, H. Uramoto, and H. Izumi p73 independent of c-Myc represses transcription of platelet-derived growth factor beta-receptor through interaction with NF-Y J Biol Chem 277 2002 39769 39776
19. A. Waltermann, N.N. Kartasheva, and M. Dobbelstein Differential regulation of p63 and p73 expression Oncogene 22 2003 5686 5693
20. B.J. Park, S.J. Lee, and J.I. Kim Frequent alteration of p63 expression in human primary bladder carcinomas Cancer Res 60 2000 3370 3374
21. C. Maisse, P. Guerrieri, and G. Melino p73 and p63 protein stability: the way to regulate function? Biochem Pharmacol 66 2003 1555 1561
22. G. Wu, S. Nomoto, and M.O. Hoque DeltaNp63alpha and TAp63alpha regulate transcription of genes with distinct biological functions in cancer and development Cancer Res 63 2003 2351 2357
23. K.E. King, R.M. Ponnamperuma, and T. Yamashita DeltaNp63alpha functions as both a positive and a negative transcriptional regulator and blocks in vitro differentiation of murine keratinocytes Oncogene 22 2003 3635 3644
24. K. Hibi, S. Fujitake, and T. Takase Identification of S100A2 as a target of the DeltaNp63 oncogenic pathway Clin Cancer Res 9 2003 4282 4285